Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer

Oncologist

Volumn 19, Issue 2, 2014, Pages 135-150

  Eroglu, Zeynep ^a   Tagawa, Tomoko ^b   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Epidermal growth factor receptor; Human epidermal growth factor receptor tyrosine kinase receptor family; Tyrosine kinase inhibitor

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; BUPARLISIB; CAPECITABINE; CARBOPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DACTOLISIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; FLUOROURACIL; GANITUMAB; GEFITINIB; IMETELSTAT; INK 128; LAPATINIB; LAPATINIB PLUS PAZOPANIB; LETROZOLE; LUMINESPIB; MM 111; NAVELBINE; NERATINIB; PACLITAXEL; PAZOPANIB; PB 272; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CLINICAL TRIAL (TOPIC); ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DISEASE COURSE; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; MOLECULARLY TARGETED THERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84894107205     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0283     Document Type: Article

References (126)

1. Flynn JF, Wong C, Wu JM. Anti-EGFR therapy: Mechanism and advances in clinical efficacy in breast cancer. J Oncol 2009;2009:526963.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
3. Sassen A, Rochon J, Wild P et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008;10: R2.
4. WittonCJ, Reeves JR, Going JJ et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-297.
5. Rimawi MF, Shetty PB, Weiss HL et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010;116:1234-1242.
6. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700-5706.
7. Herceptin (trastuzumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2010.
8. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838-5847.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed 2001;344:783-792.
10. Vogel CL, Cobleigh MA, TripathyDet al. Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
11. Baselga J, Carbonell X, Castañeda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23: 2162-2171.
12. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.
13. Huober J, Fasching PA, BarsoumMet al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as firstline treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer-results of the eLEcTRA trial. Breast 2012;21:27-33.
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl JMed 2005;353: 1659-1672.
15. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
16. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
17. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxelor vinorelbine, withorwithouttrastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009;27: 5685-5692.
18. Goldhirsch A, Piccart M, ProcterMet al. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up[Abstract LBA6]. AnnOncol 2012;23 (suppl 9):ixe2a.
19. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEngl JMed 2006;354:809-820.
20. Pivot X, RomieuG, BonnefoiHet al. PHARE trial results comparing 6 to 12months of trastuzumab in adjuvant early breast cancer [Abstract LBA5]. Ann Oncol 2012;23(suppl 9):ixe2a.
21. Buzdar AU, Valero V, Ibrahim NK et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-233.
22. Buzdar A, Suman VJ, Meric-Bernstam F et al. ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC? P1T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P1T? FEC1T) in HER21 operable breast cancer [Abstract 502]. J Clin Oncol 2013;31 (suppl).
23. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatmentwith trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024-2031.
24. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375: 377-384.
25. Gianni L, Eiermann W, Semiglazov V et al. Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT1H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer [Abstract 503]. J Clin Oncol 2013;31(suppl).
26. Tarceva (erlotinib tablets) [package insert]. South San Francisco, CA: Genentech, Inc.; 2013.
27. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-7670.
28. Dickler MN, Cobleigh MA, Miller KD et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009;115:115-121.
29. Britten CD, Finn RS, Bosserman LD et al. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer 2009; 9:16-22.
30. Iressa (gefitinib tablets) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2005.
31. Arteaga CL, O'Neill A, Moulder SL et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008;14:6277-6283.
32. Somlo G, Martel CL, Lau SK et al. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Res Treat 2012;131:899-906.
33. Burris HA 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-5313.
34. Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer thatoverexpressesHER-2. TheOncologist 2008;13:1114-1119.
35. TYKERB (lapatinib) tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
36. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
37. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
38. Gelmon KA, Boyle F, Kaufman B et al. Openlabel phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919 [Abstract LBA671]. J Clin Oncol 2012;30 (suppl).
39. Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 2012;13:135-144.
40. Goss PE, Smith IE, O'Shaughnessy J et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:88-96.
41. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-1130.
42. Crown JP, Moulton B, O'DonovanN. A phase III randomized study of paclitaxel and trastuzumab versus paclitaxel, trastuzumab and lapatinib in first line treatment of HER2 positive metastatic breast cancer [Abstract OT1-1-06]. Cancer Res 2012;72 (suppl 3). Paper presented at: San Antonio Breast Cancer Symposium (CTRC-AACR); December 4-8, 2012; San Antonio, TX.
43. Johnston S, Wroblewski S, Huang Y et al. ALTERNATIVE: Safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (AI) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer [Abstract OT1-1-04]. Cancer Res 2012;72(suppl 3). Paper presented at: San Antonio Breast Cancer Symposium (CTRCAACR); December 4-8, 2012; San Antonio, TX.
44. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial. Lancet 2012;379: 633-640.
45. Robidoux A, Tang G, Rastogi P et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER21operable breast cancer: NSABP protocol B-41 [Abstract LBA506]. J Clin Oncol 2012;30(suppl).
46. Carey LA, Berry DA, Ollila D et al. Clinical and translational results ofCALGB40601:Aneoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer [Abstract 500]. J Clin Oncol 2013;31(suppl).
47. Valachis A, Nearchou A, Lind P et al. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a metaanalysis of randomized evidence. Breast Cancer Res Treat 2012;135:655-662.
48. Rimawi MF, Mayer IA, Forero A et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013;31:1726-1731.
49. Puma Biotechnology Inc. Puma Biotechnology announces licensing agreement with Pfizer for the development and commercialization of neratinib, an investigational PanHER inhibitor; closes $55 million private placement and completes merger. Available at http://www.pumabiotechnology.com/ pr20111005.html. Accessed February 16, 2012.
50. Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-3965.
51. Tsou HR, Overbeek-Klumpers EG, Hallett WA et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 2005;48:1107-1131.
52. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-1307.
53. Awada A, Dirix L, Manso Sanchez L et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 2013;24:109-116.
54. Chow LW, Xu B, Gupta S et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer 2013;108:1985-1993.
55. Martin M, Bonneterre J, Geyer CE, Jr. et al. A phase 2, randomized, open-label, study of neratinib (HKI-272) vs. lapatinib plus capecitabine for 2nd/ 3rd-line treatment of HER21 locally advanced or metastatic breast cancer [Abstract S5-7]. Cancer Res 2011;71(suppl):113sa.
56. Jankowitz RC, Abraham J, TanARet al. Aphase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8 [Abstract 611]. J Clin Oncol 2012;30(suppl).
57. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-4711.
58. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-350.
59. Lin NU, Winer EP, Wheatley D et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012;133:1057-1065.
60. Rimawi MF, Aleixo SB, Rozas AA et al. A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC) [Abstract 606]. J Clin Oncol 2012;30(suppl).
61. Hickish T, Tseng L-M, Mehta AO et al. LUXbreast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L) [Abstract TPS651]. J Clin Oncol 2012;30(suppl).
62. Joensuu H, Kaci MO. LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy [Abstract TPS647]. J Clin Oncol 2012;30(suppl).
63. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-328.
64. PERJETA (pertuzumab) for injection, for intravenous use [package insert]. South San Francisco, CA: Genentech, Inc.; 2012.
65. Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
66. Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-471.
67. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
68. Schneeweiss A, Chia S, Hickish T et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-freechemotherapyregimensinpatients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278-2284.
69. McDonagh CF, Huhalov A, Harms BD et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012;11:582-593.
70. LewisPhillipsGD, Li G, DuggerDLet al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-9290.
71. KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use [package insert]. South San Francisco, CA: Genentech, Inc.; 2013.
72. LoRusso P, Krop IE, Burris HA III et al. Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC)whohadprogressed on prior HER2-directed therapy [Abstract 1016]. J Clin Oncol 2010;28(suppl).
73. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
74. Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013;31:1157-1163.
75. Dang CT, Gianni L, Romieu G et al. Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for earlystage HER2-positive breast cancer [Abstract 532J]. J Clin Oncol 2012;30(suppl).
76. Diermeier-Daucher S, Breindl S, Buchholz S et al. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors. Cytometry A 2011;79:684-693.
77. Atalay G, Cardoso F, Awada A et al. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003;14:1346-1363.
78. Dua R, Zhang J, Nhonthachit P et al. EGFR overexpression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 2010;122:685-697.
79. Testa JR, Bellacosa A. AKTplays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98: 10983-10985.
80. Kallergi G, Agelaki S, Kalykaki A et al. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 2008;10:R80.
81. Tokunaga E, Kimura Y, Oki E et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006;118: 284-289.
82. Baselga J, Cortes J, Im S-A et al. Biomarker analyses in CLEOPATRA: A phase III, placebocontrolled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) [Abstract S5-1]. CancerRes2012;72(suppl 3). Paper presented at: San Antonio Breast Cancer Symposium (CTRCAACR); December 4-8, 2012; San Antonio, TX.
83. Von Hoff DD, Lo RP, Tibes R et al. A first-inhuman phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors [Abstract 2541]. J Clin Oncol 2010;28:7sa.
84. Pistilli B, Urruticoechea A, Chan S et al. Ph IB/II study of BKM120 plus trastuzumab (T) in patients with T-resistant HER21 advanced breast cancer (BC) [Abstract 3180]. Ann Oncol 2012;23(suppl 9): ix116a.
85. Brachmann SM, Hofmann I, Schnell C et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009;106:22299-22304.
86. Goncalves A, Isambert N, Campone M et al. PIKHER2: A phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib inHER2-positive, PI3K-activated, trastuzumabresistant advanced breast cancer [Abstract TPS663]. J Clin Oncol 2013;31(suppl).
87. KropIE, SauraC, RodonAhnert J et al. Aphase I/ IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER21 metastatic breast cancer [Abstract 508]. J Clin Oncol 2012;30(suppl).
88. Han HS, Swanton C, Janjigian YY et al. A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors [Abstract 3028]. J Clin Oncol 2011;29(suppl).
89. Chien AJ, Truong TG, MeliskoME et al. Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER21) cancer [Abstract 2605]. J Clin Oncol 2013;31(suppl).
90. Afinitor (everolimus) tablets, for oral administration [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
91. Morrow PK, Wulf GM, Ensor J et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011; 29:3126-3132.
92. Jerusalem G, Fasolo A, Dieras V et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pretreated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011; 125:447-455.
93. Andre F, Campone M, O'Regan R et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010;28:5110-5115.
94. O'Regan R, Ozguroglu M, Andre F et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3) [Abstract 505]. J Clin Oncol 2013;31(suppl).
95. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-5322.
96. Yardley DA, Seiler M, Ray-Coquard I et al. Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter phase 2 clinical trial [Abstract 3091]. Cancer Res 2009;69(suppl).
97. LuY, Zi X, ZhaoY et al. Insulin-likegrowthfactor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-1857.
98. Modi S, Stopeck AT, Linden HM et al. HSP90 inhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17aag) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;;17::5132-5139.
99. Kong A, Rea D, Ahmed S et al. Phase IB/II study of the HSP90 inhibitor AUY922, in combinationwith trastuzumab, in patients with HER21 advanced breast cancer [Abstract 530]. J Clin Oncol 2012;30 (suppl).
100. Goldblatt EM, Erickson PA, Gentry ER et al. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Res Treat 2009;118: 21-32.
101. Miller KD, Stedin CE, PrasadN et al. Inhibiting telomerase to reverse trastuzumab (T) resistance in HER21 breast cancer [Abstract P5-18-13]. Cancer Res 2012;72(suppl 3). Paper presented at: San Antonio Breast Cancer Symposium (CTRC-AACR); December 4-8, 2012; San Antonio, TX.
102. Konecny GE, Meng YG, Untch M et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-1716.
103. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation frommousetohumanwithpazopanib, amultikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6: 2012-2021.
104. Johnston SR, Gomez H, Stemmer SM et al. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013;137: 755-766.
105. Cristofanilli M, Johnston SR, Manikhas A et al. A randomized phase II study of lapatinib 1 pazopanib versus lapatinib in patients with HER21 inflammatory breast cancer. Breast Cancer Res Treat 2013;137:471-482.
106. SUTENT (sunitinib malate) capsules, oral [package insert]. New York, NY: Pfizer Inc.; 2011.
107. Cardoso F, Canon JL, Amadori D et al. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Breast 2012;21:716-723.
108. Fernandez M, Calvo I, Martinez N et al. Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER) [Abstract P1-14-10]. Cancer Res 2012;72(suppl 3). Paper presented at: San Antonio Breast Cancer Symposium (CTRC-AACR); December 4-8, 2012; San Antonio, TX.
109. MartínM, Makhson A, Gligorov J et al. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. The Oncologist 2012;17: 469-475.
110. Lin NU, Seah DS, Gelman R et al. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013;139: 403-410.
111. Gianni L, Romieu GH, Lichinitser M et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013;31:1719-1725.
112. Arteaga CL, Mayer IA, O'Neill AM et al. A randomized phase III double-blinded placebocontrolled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER21 MBC): A trial of the Eastern Cooperative Oncology Group (E1105). J Clin Oncol 2012;30:605a.
113. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
114. Esserman LJ, Berry DA, Cheang MC et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012;132:1049-1062.
115. Xia W, Bacus S, Hegde P et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006;103:7795-7800.
116. Nahta R, O'Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 2012;135: 39-48.
117. Vaz Duarte Luis IM, Ottesen RA, Hughes ME et al. Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN) [Abstract 599]. J Clin Oncol 2012;30(suupl).
118. Paik S, Kim C, Wolmark N. HER2 status and benefit fromadjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-1411.
119. Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009;118:523-530.
120. Somlo G, Lau SK, Frankel P et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/ inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011;128:155-163.
121. Lindström LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughouttumor progression. J Clin Oncol 2012;30:2601-2608.
122. Lin NU, Danso MA, David AK et al. Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515) [Abstract TPS664599]. J Clin Oncol 2013;31(suppl).
123. Swanton C, Cromer J. Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC) [Abstract TPS650]. J Clin Oncol 2012;30(suppl).
124. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II studyof the antibodydrug conjugatetrastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29: 398-405.
125. Ellis PA, Barrios CH, ImY et al. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for firstline treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC) [Abstract TPS102]. J Clin Oncol 2011; 29(suppl).
126. Hurvitz SA, Andre F, BurrisHA et al. BOLERO-1: A randomized, phase III, double-blind, placebocontrolled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC) [Abstract TPS648]. J ClinOncol 2012;30 (suppl).